beyond glp 1 GLP-1-based therapies for diabetes, obesity and Redefining Obesity Treatment Beyond GLP-1

The compound may benefit your heart, skin, and eye health

A 1mg intranasal dose could theoretically match or exceed the brain exposure of a 3mg oral dose, though nasal administration introduces variability based on mucosal absorption and nasal cavity drainage

Our model projects that the lower average BMI for insured groups has more impact than the increased ability to access the drugs, and so the overall mortality and morbidity impact is typically lower than for the general population

Non-surgical methods are lower risk, but less dramatic than surgery

Diabetic ketoacidosis (DKA) presents with extreme thirst, frequent urination, nausea, abdominal pain, and fruity-smelling breath